The verdict
Our read at a glance.
Whether a triple monoamine reuptake inhibitor can deliver large weight loss at a dose that does not raise blood pressure, heart rate, or psychiatric risk, and whether the pivotal trial's reported safety data can be relied upon.
- The signal
- The phase II trial randomized 203 patients with obesity across five Danish centres to tesofensine 0.25, 0.5 or 1.0 mg or placebo for 24 weeks on an energy-restricted diet. Reported placebo-subtracted weight loss was about 4.5 kg, 9.1 kg and 10.6 kg across the ascending doses. Separate randomized work examined its effects on appetite sensations and energy metabolism, which is where the mechanism sits: blocking presynaptic reuptake of noradrenaline, dopamine and serotonin.
- The unknown
- Whether the efficacy survives honest, complete adverse-event accounting, and whether any dose separates weight loss from the cardiovascular and psychiatric effects. No phase III programme has resolved this, so the drug's risk-benefit profile at scale is genuinely unestablished rather than merely unpublished.
- Our read
- Read the effect size and the Expression of Concern together or not at all. The weight-loss numbers are the reason people still talk about this drug, and the reason to be careful is printed in the same journal that published them. On a Watchlist that grades evidence, a disputed pivotal trial is a finding, not a footnote.
The mechanism
How it works.
Safety & regulatory boundary
The consequential part.
This is the rare memo where the evidence itself is contested. PubMed records an Expression of Concern from the Lancet against the 2008 trial, and separate published correspondence raised under-reporting of adverse effects in the programme. An Expression of Concern is not a retraction, and it is not a clearance either; it is the journal telling readers to treat the paper carefully. On top of that, the trial itself reported increased blood pressure and heart rate. Tesofensine is not FDA-approved and not EMA-approved.
What's next
What we're watching.
Any resolution of the Expression of Concern, any phase III programme with modern cardiovascular safety monitoring, and independent replication of the efficacy under complete adverse-event reporting.
Context
Why this is discussed.
The headline efficacy is genuinely large, roughly double the approved drugs of its era, and it is orally available and cheap, so it keeps resurfacing in obesity discussion and in grey-market sales.
The evidence base
4 cited references.
Peer-reviewed journals1
Indexed literature (PubMed)3
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM (Lancet) · 2008
Correspondence (Lancet) · 2013
Sjodin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A (Obesity, Silver Spring) · 2012
Keep reading